Press Releases

Back to previous page

ReGen Biologics Tissue Growth Data Presented

FRANKLIN LAKES, NJ – June 20, 2006 – ReGen Biologics today announced that data from its CMI™ MultiCenter Study will be featured in a poster presentation at the American Orthopedic Society for Sports Medicine (AOSSM) meeting to be held in Hershey, Pennsylvania beginning June 29, 2006.

The poster is entitled “New Tissue Growth after Collagen Meniscus Implant (CMI) Placement into Meniscus Defects.”  It was authored by William G. Rodkey, D.V.M., J. Richard Steadman, M.D., William Montgomery, III, M.D., Scott Hormel, M.D. and Karen Briggs, M.P.H.

“This poster is another result of ReGen’s ongoing programs to analyze and report on the important data from our clinical studies,” commented Gerald E. Bisbee, Jr., Ph.D., Chairman and Chief Executive Officer of ReGen Biologics.  “The sports medicine community provides an excellent forum for discussion, given the active patient as an important audience for the product.”

About ReGen Biologics, Inc.
ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen's patented collagen scaffold technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery.  The Company’s first approved product using its collagen scaffold technology is the CMI™, a meniscus application of its collagen scaffold technology, which is cleared for sale in Europe and marketed through the Company’s European subsidiary ReGen Biologics AG.

ReGen is headquartered in Franklin Lakes, NJ and manufactures its collagen scaffold products in its ISO Certified facility located in Redwood City, CA.  For more information on ReGen, visit www.regenbio.com.

This press release contains forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on the current expectations and beliefs of the management of ReGen and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including those discussed in the Risk Factors section of ReGen's 2005 annual report on Form 10-K and additional filings with the SEC. ReGen's filings with the SEC are available to the public at the Company's website at http://www.regenbio.com, from commercial document-retrieval services, and at the Web site maintained by the SEC at http://www.sec.gov.

Contacts:
ReGen Biologics, Inc.
Brion Umidi
Chief Financial Officer
(201) 651-3515
bumidi@regenbio.com

Cameron Associates
Al Palombo
Investor Relations
(212) 245-8800 Ext. 209
al@cameronassoc.com

For Meeting Information:
American Orthopedic Society for Sports Medicine  www.aossm.org

(OTC:RGBI) ...